Skip to main content
main-content
Erschienen in: Der Pathologe 1/2022

03.01.2022 | Hepatozelluläres Karzinom | CME

Pathologie des Hepatozellulären Karzinoms

verfasst von: Prof. Dr. med. Thomas Longerich, Prof. Dr. med. Peter Schirmacher

Erschienen in: Die Pathologie | Ausgabe 1/2022

zum CME-Kurs Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Hepatozelluläre Karzinom (HCC) ist die dritthäufigste krebsbedingte Todesursache weltweit und hat eine klar definierte Ätiologie. Es entsteht über morphologisch definierte Vorstufen. Neben histopathologischen Kriterien können immunhistologische Markerkombinationen und die sog. Matrixdiagnose bei der diagnostischen Einordnung hochdifferenzierter hepatozellulärer Tumoren helfen. In der aktuellen Klassifikation der Weltgesundheitsorganisation (WHO) wurden morphomolekulare HCC-Subtypen definiert, die mit klinischen und prognostischen Charakteristika assoziiert sind. Sofern HCC-Subtypen in künftigen Therapiestudien des fortgeschrittenen HCC Berücksichtigung finden, könnte dies zu einer Personalisierung der HCC-Therapie beitragen. Aktuell gibt es keine präzisionsonkologische Therapie des HCC.
Literatur
1.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424 CrossRef Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424 CrossRef
2.
Zurück zum Zitat International Consensus Group for Hepatocellular Neoplasia (2009) Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49:658–664 CrossRef International Consensus Group for Hepatocellular Neoplasia (2009) Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49:658–664 CrossRef
3.
Zurück zum Zitat Park YN, Yang CP, Fernandez GJ et al (1998) Neoangiogenesis and sinusoidal “capillarization” in dysplastic nodules of the liver. Am J Surg Pathol 22:656–662 CrossRef Park YN, Yang CP, Fernandez GJ et al (1998) Neoangiogenesis and sinusoidal “capillarization” in dysplastic nodules of the liver. Am J Surg Pathol 22:656–662 CrossRef
4.
Zurück zum Zitat Kondo F, Wada K, Nagato Y et al (1989) Biopsy diagnosis of well-differentiated hepatocellular carcinoma based on new morphologic criteria. Hepatology 9:751–755 CrossRef Kondo F, Wada K, Nagato Y et al (1989) Biopsy diagnosis of well-differentiated hepatocellular carcinoma based on new morphologic criteria. Hepatology 9:751–755 CrossRef
5.
Zurück zum Zitat Kondo F, Kondo Y, Nagato Y et al (1994) Interstitial tumour cell invasion in small hepatocellular carcinoma. Evaluation in microscopic and low magnification views. J Gastroenterol Hepatol 9:604–612 CrossRef Kondo F, Kondo Y, Nagato Y et al (1994) Interstitial tumour cell invasion in small hepatocellular carcinoma. Evaluation in microscopic and low magnification views. J Gastroenterol Hepatol 9:604–612 CrossRef
6.
Zurück zum Zitat Park YN, Kojiro M, Di Tommaso L et al (2007) Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules. Cancer 109:915–923 CrossRef Park YN, Kojiro M, Di Tommaso L et al (2007) Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules. Cancer 109:915–923 CrossRef
7.
Zurück zum Zitat Di Tommaso L, Franchi G, Park YN et al (2007) Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 45:725–734 CrossRef Di Tommaso L, Franchi G, Park YN et al (2007) Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 45:725–734 CrossRef
8.
Zurück zum Zitat Abdul-Al HM, Makhlouf HR, Wang G et al (2008) Glypican‑3 expression in benign liver tissue with active hepatitis C: implications for the diagnosis of hepatocellular carcinoma. Hum Pathol 39:209–212 CrossRef Abdul-Al HM, Makhlouf HR, Wang G et al (2008) Glypican‑3 expression in benign liver tissue with active hepatitis C: implications for the diagnosis of hepatocellular carcinoma. Hum Pathol 39:209–212 CrossRef
9.
Zurück zum Zitat Chuma M, Sakamoto M, Yamazaki K et al (2003) Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology 37:198–207 CrossRef Chuma M, Sakamoto M, Yamazaki K et al (2003) Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology 37:198–207 CrossRef
10.
Zurück zum Zitat Di Tommaso L, Destro A, Seok JY et al (2009) The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 50:746–754 CrossRef Di Tommaso L, Destro A, Seok JY et al (2009) The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 50:746–754 CrossRef
11.
Zurück zum Zitat Zucman-Rossi J, Benhamouche S, Godard C et al (2007) Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene 26:774–780 CrossRef Zucman-Rossi J, Benhamouche S, Godard C et al (2007) Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene 26:774–780 CrossRef
12.
Zurück zum Zitat Bioulac-Sage P, Laumonier H, Rullier A et al (2009) Over-expression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology. Liver Int 29:459–465 CrossRef Bioulac-Sage P, Laumonier H, Rullier A et al (2009) Over-expression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology. Liver Int 29:459–465 CrossRef
13.
Zurück zum Zitat Longerich T, Endris V, Neumann O et al (2019) RSPO2 gene rearrangement: a powerful driver of beta-catenin activation in liver tumours. Gut 68:1287–1296 CrossRef Longerich T, Endris V, Neumann O et al (2019) RSPO2 gene rearrangement: a powerful driver of beta-catenin activation in liver tumours. Gut 68:1287–1296 CrossRef
14.
Zurück zum Zitat Paradis V, Fukayama M, Park YN et al (2019) Tumours of the liver and intrahepatic bile ducts. In: Lokuhetty D, White VA, Watanabe R, Cree IA (Hrsg) WHO classification of tumours—digestive system tumours. International Agency for Research on Cancer (IARC), Lyon, S 215–264 Paradis V, Fukayama M, Park YN et al (2019) Tumours of the liver and intrahepatic bile ducts. In: Lokuhetty D, White VA, Watanabe R, Cree IA (Hrsg) WHO classification of tumours—digestive system tumours. International Agency for Research on Cancer (IARC), Lyon, S 215–264
15.
Zurück zum Zitat Honeyman JN, Simon EP, Robine N et al (2014) Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 343:1010–1014 CrossRef Honeyman JN, Simon EP, Robine N et al (2014) Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 343:1010–1014 CrossRef
16.
Zurück zum Zitat Graham RP, Yeh MM, Lam-Himlin D et al (2018) Molecular testing for the clinical diagnosis of fibrolamellar carcinoma. Mod Pathol 31:141–149 CrossRef Graham RP, Yeh MM, Lam-Himlin D et al (2018) Molecular testing for the clinical diagnosis of fibrolamellar carcinoma. Mod Pathol 31:141–149 CrossRef
17.
Zurück zum Zitat Ziol M, Pote N, Amaddeo G et al (2018) Macrotrabecular-massive hepatocellular carcinoma: a distinctive histological subtype with clinical relevance. Hepatology 68:103–112 CrossRef Ziol M, Pote N, Amaddeo G et al (2018) Macrotrabecular-massive hepatocellular carcinoma: a distinctive histological subtype with clinical relevance. Hepatology 68:103–112 CrossRef
18.
Zurück zum Zitat Wood LD, Heaphy CM, Daniel HD et al (2013) Chromophobe hepatocellular carcinoma with abrupt anaplasia: a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features. Mod Pathol 26:1586–1593 CrossRef Wood LD, Heaphy CM, Daniel HD et al (2013) Chromophobe hepatocellular carcinoma with abrupt anaplasia: a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features. Mod Pathol 26:1586–1593 CrossRef
19.
Zurück zum Zitat Yamamoto S, Takashima S, Ogawa H et al (1999) Granulocyte-colony-stimulating-factor-producing hepatocellular carcinoma. J Gastroenterol 34:640–644 CrossRef Yamamoto S, Takashima S, Ogawa H et al (1999) Granulocyte-colony-stimulating-factor-producing hepatocellular carcinoma. J Gastroenterol 34:640–644 CrossRef
20.
Zurück zum Zitat Calderaro J, Rousseau B, Amaddeo G et al (2016) Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features. Hepatology 64:2038–2046 CrossRef Calderaro J, Rousseau B, Amaddeo G et al (2016) Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features. Hepatology 64:2038–2046 CrossRef
21.
Zurück zum Zitat Chan AW, Tong JH, Pan Y et al (2015) Lymphoepithelioma-like hepatocellular carcinoma: an uncommon variant of hepatocellular carcinoma with favorable outcome. Am J Surg Pathol 39:304–312 CrossRef Chan AW, Tong JH, Pan Y et al (2015) Lymphoepithelioma-like hepatocellular carcinoma: an uncommon variant of hepatocellular carcinoma with favorable outcome. Am J Surg Pathol 39:304–312 CrossRef
22.
Zurück zum Zitat Finn RS, Qin S, Ikeda M et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894–1905 CrossRef Finn RS, Qin S, Ikeda M et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894–1905 CrossRef
23.
Zurück zum Zitat Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391:1163–1173 CrossRef Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391:1163–1173 CrossRef
24.
Zurück zum Zitat Abou-Alfa GK, Meyer T, Cheng AL et al (2018) Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 379:54–63 CrossRef Abou-Alfa GK, Meyer T, Cheng AL et al (2018) Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 379:54–63 CrossRef
25.
Zurück zum Zitat Bruix J, Qin S, Merle P et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389:56–66 CrossRef Bruix J, Qin S, Merle P et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389:56–66 CrossRef
26.
Zurück zum Zitat Zhu AX, Park JO, Ryoo BY et al (2015) Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 16:859–870 CrossRef Zhu AX, Park JO, Ryoo BY et al (2015) Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 16:859–870 CrossRef
27.
Zurück zum Zitat Cancer Genome Atlas Research Network (2017) Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 169:1327–1341.e23 CrossRef Cancer Genome Atlas Research Network (2017) Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 169:1327–1341.e23 CrossRef
28.
Zurück zum Zitat Kim RD, Sarker D, Meyer T et al (2019) First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma. Cancer Discov 9:1696–1707 CrossRef Kim RD, Sarker D, Meyer T et al (2019) First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma. Cancer Discov 9:1696–1707 CrossRef
29.
Zurück zum Zitat Schlaeger C, Longerich T, Schiller C et al (2008) Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology 47:511–520 CrossRef Schlaeger C, Longerich T, Schiller C et al (2008) Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology 47:511–520 CrossRef
30.
Zurück zum Zitat Xie B, Zhou J, Yuan L et al (2013) Epigenetic silencing of Klotho expression correlates with poor prognosis of human hepatocellular carcinoma. Hum Pathol 44:795–801 CrossRef Xie B, Zhou J, Yuan L et al (2013) Epigenetic silencing of Klotho expression correlates with poor prognosis of human hepatocellular carcinoma. Hum Pathol 44:795–801 CrossRef
31.
Zurück zum Zitat Nault JC, Martin Y, Caruso S et al (2020) Clinical impact of genomic diversity from early to advanced hepatocellular carcinoma. Hepatology 71:164–182 CrossRef Nault JC, Martin Y, Caruso S et al (2020) Clinical impact of genomic diversity from early to advanced hepatocellular carcinoma. Hepatology 71:164–182 CrossRef
32.
Zurück zum Zitat Rimassa L, Assenat E, Peck-Radosavljevic M et al (2018) Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol 19:682–693 CrossRef Rimassa L, Assenat E, Peck-Radosavljevic M et al (2018) Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol 19:682–693 CrossRef
33.
Zurück zum Zitat Kurebayashi Y, Ojima H, Tsujikawa H et al (2018) Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology 68:1025–1041 CrossRef Kurebayashi Y, Ojima H, Tsujikawa H et al (2018) Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology 68:1025–1041 CrossRef
34.
Zurück zum Zitat Sia D, Jiao Y, Martinez-Quetglas I et al (2017) Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. Gastroenterology 153:812–826 CrossRef Sia D, Jiao Y, Martinez-Quetglas I et al (2017) Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. Gastroenterology 153:812–826 CrossRef
Metadaten
Titel
Pathologie des Hepatozellulären Karzinoms
verfasst von
Prof. Dr. med. Thomas Longerich
Prof. Dr. med. Peter Schirmacher
Publikationsdatum
03.01.2022
Verlag
Springer Medizin
Erschienen in
Die Pathologie / Ausgabe 1/2022
Print ISSN: 2731-7188
Elektronische ISSN: 2731-7196
DOI
https://doi.org/10.1007/s00292-021-01038-0

Weitere Artikel der Ausgabe 1/2022

Der Pathologe 1/2022 Zur Ausgabe

Mitteilungen der Österreichischen Gesellschaft für Klinische Pathologie und Molekularpathologie

Mitteilungen der Österreichischen Gesellschaft für Klinische Pathologie und Molekularpathologie

Schwerpunkt: Gastrointestinale Pathologie

Histologic features of colonic infections